Diligence memo · auto-generated · as of July 3, 2026
Halda Therapeutics, LLC
Halda Therapeutics, LLC looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Halda Therapeutics, LLC operates in Pharma, based in NEW HAVEN.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Halda Therapeutics, LLC has raised $198M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $126M on 2024-07-31.
Most recent recorded round closed around 2024-07-31.
Valuation (modeled)modeled
Provath models Halda Therapeutics, LLC at approximately $1.3B (range $602M–$1.8B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.65× the median modeled value of Series D+ Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 22 months.
Last raise 23 mo ago; this sector typically re-raises about every 16 months.
Slightly overdue versus sector cadence.
The last round stepped up 5.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 97% of Pharma peers (310 compared).
Modeled value ranks above 92% of those peers.
Closest niche peers: Mirador Therapeutics, Inc., Autolus Therapeutics plc, Candid Therapeutics, Inc., Bluejay Therapeutics, Inc., Bright Peak Therapeutics, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.